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Epidemiological studies suggest that consumption of
isoflavones rich diets can improve several postmenopausal
complications. The aim of this study was to investigate the
absorption and the efficacy of isoflavonic supplementation
in the treatment of menopausal symptoms.
36 postmenopausal women received 75 mg/day of isoflavones in
the form of tablets, for six months. 21 subjects concluded the
treatment. Plasmatic and urinary samples were collected before
and after the treatment, along with a dietary interview. Isoflavones
were determined in biological samples and in commercial admin-
istered supplements by a HPLC/DAD system. 
Results showed the presence of genistein (from 0.043 to 1.820
micromol/L) in plasma samples, and of genistein (from 2.486
to 20.363 micromol/24h) and daidzein (from 11.106 to 98.091
micromol/24h) in the urines of the treated women. In the 21
completers the Greene Climateric scale value for hot flushes
changed from 3 to 1 or 0. No changes of the endometrial thick-
ness and of the breast tissue were detected. The analysis of
the supplement content in the tablets was in agreement with
what declared by the producer.
Administration of isoflavone supplements produced a de-
crease of symptoms in this cohort of postmenopausal women
monitored for isoflavone absorption. 
KEY  WORDS: phytoestrogens, isoflavones, HPLC analysis, menopause, hot
flushes.
Introduction
Phytoestrogens are a group of polyphenolic compounds de-
rived from plants that bear a similarity to estrogens in their
chemical structure and biological properties (1). The soy
isoflavones, genistein and daidzein, are the most extensively
studied compounds (2). The main sources of these compounds
are in the order, traditional soy foods, second generation soy
foods, gluten-free aliments, legumes like broad beans, red
beans, fresh podded peas, red clover sprouts, some species of
Solanaceae, and milk of red clover fed cows (3-7). The agli-
cone is the available chemical form for intestinal absorption, as
such or in a more hydrophilic form bound to a molecule of glu-
curonic or sulphuric acid (8). The conjugated molecules can
pass the enterohepatic circle (9) and return at the intestinal lev-
el where they are converted into different metabolites (10). The
pharmacokinetic analysis of isoflavones in humans supported
the theoretical model of their enterohepatic recirculation, sug-
gesting that this mechanism is the way used to increase their
“in vivo” half-life (11). The metabolites that do not enter in the
enterohepatic recycle are eliminated through the urines, while
the final metabolites are eventually eliminated in small quanti-
ties with the faeces (12). Usually the urinary excretion for
daidzein is higher than for genistein and this can be explained
for its facility to take the biliary route (13). In the absorption effi-
ciency of isoflavones, the intestinal flora plays an important role
at three different levels: hydrolysis of glucosides, degradation
and conjugation. However, the intestinal bacterial population
responsible for these functions has not been identified yet (10).
The role of the intestinal flora in determining the bioavailability
of isoflavones is supported by the fact that every variable that
affects the intestinal microenviroment (antibiotics, laxatives, in-
testinal diseases) can modify the metabolism of these com-
pounds, making of the healthy intestinal condition a prerequi-
site for phytoestrogen administration. 
Another factor recognized to influence the phytoestrogen
bioavailability is the genetic difference in the capability to me-
tabolize these molecules. Indeed, in humans only 30-50% of
the treated subjects is able to produce equol from daidzein and
80-90% of this group can produce O-desmethylangolensin (O-
DMA) (9). The capacity to produce equol is increased in the
equol-producers subjects fed with a diet rich in carbohydrates
and fibres and poor in fats and, therefore, capable to increase
the intestinal fermentation (11).
Other conditions capable to influence the bioavailability of
isoflavones are the alimentary matrix even though the absorp-
tion facilitator complex for phytoestrogens is unknown (14). An-
other variable is the type of administration, with microencapsu-
lation representing an ideal vehicle (15). Factors that appear
not critical for influencing isoflavone absorption are age and
gender (16, 17).
Once absorbed isoflavones have a half-life of eight hours (18),
shorter than expected for compounds capable to generate sev-
eral metabolites (19). The pharmacokinetic profile does not ap-
pear influenced by chronic exposition to soy or soy-derivatives,
supporting the fact that these compounds do not bioaccumu-
late in the organism (20).
According with their biological features, isoflavones are able to
carry out four main types of actions on estrogen-sensitive tar-
gets: no effect, an estrogenic effect, an anti-estrogenic effect
and effects non estrogenic, but unique for these molecules
(21). Genistein and daidzein are capable to bind to estrogen
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receptors (ERs) with an affinity respectively 100 and 1000 folds
lower than 17β estradiol (22) and with a greater affinity for es-
trogen receptors β (ERβ) than ERα (23). Bone, brain, bladder
and vascular vessels are rich in ERβ, while breast, uterus and
ovary express both ERα or ERβ. This different localization of
ERs can explain the capacity of isoflavones to determine a se-
lective action on the different target tissues. Antiestrogenic ef-
fects of phytoestrogens are correlated with their capability to
repress estrogenic metabolic enzymes [i.e. aromatase (24),
17β hydroxysteroid dehydrogenase, and 3β hydroxysteroid de-
hydrogenase (25)]. Finally, non estrogenic mechanisms of ac-
tion of these molecules are: a) the inhibition of angiogenesis
(26) and of cellular proliferation through the control of tyrosine
kinase and topoisomerase II enzymes (27), and b) the antioxi-
dant actions and the capability to modulate the production of
nitric oxide (28).
Dietary intake of isoflavones is estimated to be around 20-100
mg/day in Asians (29), while Europeans do not exceed 1
mg/day (0.63-1 mg/day in men and 0.49-0.66 mg/day in
women) (1). In particular classes of consumers, like vegetari-
ans, hypercholesterolemics, children and infants, the intake of
phytoestrogens is higher because of their diet composition
(30).
Epidemiological studies suggest that consumption of an
isoflavone-rich diet, common in the traditional Asian diet, is as-
sociated with an improvement both of many of the post-
menopausal complications [cardiovascular diseases (31), os-
teoporosis (32-34), hormone-dependent cancers (35),
Alzheimer’s disease (36), and diabetes (31)] and of the neu-
rovegetative symptoms [hot flushes, night sweats, irritability, in-
somnia, and mood changes (37)]. Because hormone replace-
ment therapy (HRT), that effectively prevents a number of
these problems, shows a poor long-term adherence, research
focused an alternative remedies, such as phytoestrogens.
In this study, we have selected 36 postmenopausal women
who received a daily administration of an analytically dosed
phytoestrogenic supplement during a period of six months. In
this population isoflavonic metabolites were measured in plas-
ma and urines before starting the supplementation and after six
months of treatment, with a careful monitoring of the neuroveg-
etative symptoms and of the mammary and uterine tissues.
Materials and methods
Study subjects
36 volunteers postmenopausal women (mean age 56.4 years),
selected among 242 female patients, were examined at the gy-
necology outpatient Clinic of the Bone Metabolic Unit of the
University of Florence from March to June 2006. The post-
menopausal status was determined on the basis of plasmatic
FSH values (up to 30 UI/ml) and amenorrhoea status up to 6
months. Recruitment criteria included: the presence of severe
menopausal symptoms, in particular hot flushes [score 3 of the
modified Greene Climateric Scale; (38)], endometrial thickness
≤4 mm, lack of osteoporosis, and normal serum cholesterol
levels. All the women were informed on the phytoestrogen ther-
apy, in general well accepted because of the common belief of
being “more natural” than HRT (39). Only one subject (n 7) of
the group had been previously using phytoestrogenic therapy.
All the women gave their informed consent to participate in the
study. 
In all the women a transvaginal ultrasound and a mammogra-
phy were carried out. The familial history showed osteoporosis
in 7 cases and breast cancer in 5 cases, with no detected cas-
es of colon or of endometrial cancer. The personal history re-
vealed 10 cases of uterine myomas, 2 cases of uterine polypo-
sis (treated with operative hysteroscopy), 11 cases of breast fi-
bromatosis, 5 cases of premenopausal polymenorrhea, and 2
cases of premature menopause.
The diet history administered by a certified nutritionist, was car-
ried out with the aim to evaluate the dietetic behaviour of every
subject. The recruited subjects did not consume soy foods and
derivatives in the habitual diet and did not report dietetic habits
that could negatively interfere with the phytoestrogen therapeu-
tic response. Dietary data were collected to ascertain also the
beverage intakes, including alcohol consumption. The open-
ended interview approach has been shown to produce better
estimates of energy intake at the group level than weighed-
food records. In brief, the dietary interview allowed to quantify
foods and drinks by a photographic food atlas (≈ 1000 pho-
tographs) of known portion sizes (40). Also the general style of
life, with the frequency of physical activity and smoking habit,
were recorded. Data were stored and processed using Winfood
software version 2, developed by Medimatica, Milan, Italy. This
database, that includes about 300 food items, made possible to
calculate the daily caloric intake and the quantities of principal
macro- and micro-elements (proteins, carbohydrates, lipids,
calcium and vitamin D). In line with the Mediterranean Diet ba-
sic principles, all patient received dietary instruction for a diet
poor in fats and proteins and rich in carbohydrates and vegeta-
bles. Women with a low calcium intake were advised to in-
crease the consumption of milk, milk derivatives, and calcium-
rich mineral waters. 
Treatments
All the patients received 75 mg of isoflavones once a day in the
form of supplement tablets. After six months from the begin-
ning of the treatment the subjects were recalled for a control-
visit, to revaluate the general conditions, the state of neuroveg-
etative symptoms, the eventual side effects of the therapy on
the mammary and uterine tissues, the bone mineral density
(BMD), and the potential changes in their dietetic habits. 
Samples collection and analytical methods
At the recruitment and after 6 months of phytoestrogenic thera-
py, six millilitres blood samples were collected into BD va-
cuteiner containing EDTA as an anticoagulant. The after sup-
plementation drawing has been executed 8-10 hours after the
ingestion of the phytoestrogenic supplement tablet, in corre-
spondence with the highest pharmacokinetic peak of these
molecules (16). Plasma samples were prepared and frozen at -
20°C until analysis. Sample preparation for plasma isoflavones
analysis was performed with a modification of the method de-
scribed by Manach et al. (41). To limit the isoflavones losses
the plasma were acidified with 0.58 M acetic acid solution. The
acidified samples were treated with enzymes, β-glucuronidase
and arilsulfatase (Sigma-Aldrich), to hydrolyzed the conjugated
phytoestrogens. The isoflavones extraction were performed
with organic solvent (acetone) and 20 µL of clear samples
were tested by HPLC.
Participants were provided supplies and instructed in the col-
lection of a 24-hours urine sample. The collection was conduct-
ed at the recruitment and repeated after the 6 month-supple-
mentation. In both cases the volume was recorded and two
aliquots of each sample were frozen at -20°C. Sample prepara-
tion for urine isoflavones analysis was performed according to
the methods described by Frankie et al. (42). 20 mL of clear
urine were mixed with 0.2 M acetate buffer (pH 4) and filtered
through a C18 RP-SPE column (Waters). The isoflavones were
then eluted with 100% methanol. The SPE eluates were dried
(by Speed Vac SC110 (Savant)), dissolved with 0.2 M phos-
phate buffer (pH 7) and mixed with the enzymes, β-glu-
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curonidase and arilsulfatase (Sigma-Aldrich) to hydrolyzed the
conjugated phytoestrogens. Finally an additional concentration
was performed and the organic phase redissolved before the
injection in the HPLC system. 
The separation and determination of isoflavones by the HPLC
system were obtained according to the method described by
Frankie et al. (42), appropriately modified in the gradient tim-
ing. Isoflavones compounds were separated using a HPLC an-
alytical reversed-phase column Novapak C18 (Waters, MA,
USA). The optimal separation of the target molecules was ob-
tained using a mobile phase with a three-step linear solvent
gradient system, starting from 95% H2O (adjusted to pH 3.2 by
H3PO4) up to 100% CH3CN during a 30 min period at a flow
rate of 0.8 mL/min. UV/Vis spectra were recorded in the 190-
600 nm range and the chromatograms acquired at 260 nm for
genistein and at 248 nm for daidzein.
The analyses were carried out using a HPLC system from Wa-
ters Corporation equipped with a dual pump (model 515) and a
supplied with a diode array detector (PDA 996) (Waters, MA,
USA). The data were stored and analysed with a Waters Mil-
lennium 32 software.
The commercial formulation administered to the women were
dosed with the aim to test the reliability of the isoflavonic con-
centration reported in the information sheet.
Results
The mean Body Mass Index (BMI) of the 36 studied subjects,
was 24.15 ± 3.07 kg/m2. The evaluation of the dietary composi-
tion and the dietary caloric intake of women at the recruitment
and at the end of the isoflavones administration period re-
vealed lack of differences in the diet habits. The study group
showed a mean caloric intake of 1924.75 ± 197.55 Cal. The di-
et composition of the studied group, with a partition in carbohy-
drates, lipids and proteins, is shown in Figure 1. The analysis
included also the percentage of animal and vegetal proteins,
respectively of 63.83% ± 6.02 and 36.17 % ± 6.02. The
amounts of daily mean dietary intake of calcium and of vitamin
D were respectively 845.37 ± 189.38 mg and 1.76 ± 0.47 µg.
Data about physical activity indicated that 60% of the women
under study practiced a regular physical activity, intended as
not less than twice a week.
Of the 36 women initially recruited, 21 completed the study,
while 15 women interrupted the phytoestrogenic treatment be-
cause of either for poor compliance or for personal motivations.
The adherence to phytoestrogen therapy was excellent among
completers. In women completing the six-month administration
period the Greene Climateric scale value for hot flushes
changed from 3 in the whole group, at the moment of the re-
cruitment, to 1 (in 20 %) and 0 (in 80 % of cases), after 6
month-treatment (Table I). However, these results did not show
any correlation with the levels of isoflavonic metabolites detect-
ed in plasma and in urines. Furthermore, no changes of the
myomas, endometrial thickness, and breast tissue were detect-
ed in any of the 21 completers. Moreover, no changes in BMD
were observed in the 21 completers.
The isoflavones HPLC analyses made possible to reveal both
genistein and daidzein, respectively at 260 and 248 nm in the
UV-VIS spectrum. At the recruitment all patients did not present
detectable concentrations of isoflavones either in plasma or
urines (Figures 3a and 4a), while plasma and urines collected
8-10 hr after the ingestion of the tablet [in correspondence with
the highest pharmacokinetic peak of these molecules (16)] at
the end of the six-month supplementation period showed de-
tectable amounts of genistein and daidzein (Figures 3b and 4b).
In particular, after 6 months of phytoestrogenic supplementation
only 19 out 21 subjects showed detectable amount of genistein
in plasma, while daidzein was not detectable in any sample
(Table I). Measurable levels of genistein and daidzein were ob-
served in the urines of 17 out of the 21 cases (Table I).
The analyses conducted on the phytoestrogenic supplement
tablets were carried out with the aim to validate the reliability of
the isoflavonic concentration values reported by the producer.
The obtained results were compatible with the declared value
for the commercial formulation (declared value 5,59 g/100g;
HPLC values 5,48 g/100g).
Discussion
In the last few years the use of phytoestrogenic supplements
for the treatment of menopausal symptoms has largely devel-
oped among Italian women, often in a form of “self-medication”,
without any medical prescription. This study evaluated the role
of phytoestrogen supplementation in the control of menopausal
symptoms, using an analytical method to monitor the adsorbed
orally administered isoflavones in a cohort of healthy post-
menopausal women followed by a medical équipe.
The reported dietetic habits of the participants to the study
showed a typical range value for age, gender and clinical sta-
tus (postmenopausal women around 56 years old, with normal
Figure 1 - Percentage of dietary components after the supplementation
period.
Figure 2 - Recommended percentage of macro-elements (SINU).
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lipoprotein profile and no clinical complications). The group did
not modify the dietetic caloric intake during the isoflavonic sup-
plementation period, with the BMI kept constant along the ob-
servation period and in the expected range for post-menopausal
women. The composition of the diet continued to show some
pitfalls as the diet habits were characterized by an excessive
intake in protein and fats, when compared to values recom-
mended by the Italian Society for Human Nutrition (Figure 2).
Moreover, the intake of calcium and vitamin D was lower than
what indicated by LARN (Recommend Daily Assumption Lev-
els of Nutrient for the Italian Population) (43). Interestingly, as
the carbohydrate ratio of the participants to this study did not
exceed 49% of the entire caloric intake, they could not be as-
cribed to the ≥70% category, that shows an optimal isoflavones
absorption (44). The rate between protein derived from animal
and vegetal sources was also not ideal, being higher than rec-
ommended in the post-menopausal period (45). An excessive
intake of animal proteins, favouring a low pH, causes an accel-
eration of bone mineral loss (46). This, together with the low in-
take of calcium and vitamin D for all women [average of 800
mg/day for calcium (recommended: 1200-1500 mg/die) and on-
ly 1.70 µg/day for vitamin D (recommended: 10 µg/die)], con-
tributes to the loss of bone mineral density with increased frac-
ture risk (47).
Under this dietary profile the results showed that the analytical
method applied to evaluate phytoestrogens in biological sam-
Table I - Plasmatic and urinary concentrations of isoflavones after 6 months of phytoestrogenic supplementation and entity of the symptoms
before and after the supplementation.
Sample Plasmatic Plasmatic Urinary Urinary Symptoms
Genistein Daidzein Genistein Daidzein (GCS value)*
(µmol/L) (µmol/L) (µmol/24h) (µmol/24h) Before After
1 1.593 n.d. 5.948 24.959 3 0
2 0.748 n.d. 9.054 32.792 3 0
3 1.025 n.d. 12.253 37.003 3 0
4 1,362 n.d. 12,591 36.564 3 0
5 1.342 n.d. 12.960 31.104 3 0
6 1.099 n.d. 11.533 30.568 3 0
7 0.065 n.d. 11.673 98.091 3 0
8 0.727 n.d. 14.073 32.837 3 0
9 0.126 n.d. 6.021 29.154 3 1
10 0.665 n.d. 4.664 44.915 3 0
11 0.043 n.d. 7.651 11.106 3 0
12 1.820 n.d. 12.509 31.485 3 1
13 0.347 n.d. 8.130 17.615 3 0
14 1.242 n.d. 10.325 27.457 3 1
15 0.473 n.d. 9.477 14.235 3 0
16 0.487 n.d. 5.039 26.717 3 0
17 0.508 n.d. 2.486 45.265 3 0
18 0.357 n.d. 20.363 31.343 3 0
19 0.121 n.d. 6.655 49.823 3 1
20 1.153 n.d. 14.933 40.689 3 0
21 0.459 n.d. 12.008 29.644 3 0
* Green Climateric Scale value for hot flushes.
Figure 3 - Representative chromatogram of human hydrolyzed plasma without (a) and with (b) phytoestrogenic supplementation.
A B
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ples was simple and efficacious. The results showed the ab-
sence of isoflavones metabolites in samples collected at the re-
cruitment, before the starting of the supplementation, as ex-
pected in a diet lacking soy and soy-based foods (48). The
plasmatic and the urinary concentrations of genistein (from
0.043 to 1.820 micromol/L; from 2.486 to 20.363 micromol/24h)
and the urinary concentrations of daidzein (from 11.106 to
98.091 micromol/24h), found at the end of the six-month sup-
plementation period, are in line with previously published data
(20). In agreement with the greater bioavailability of genistein
than daidzein (49), differently than in plasma, a higher daidzein
excretion was registered in the urines when compared with
genistein.
As published data about the true chemical composition of the
commercial supplements are often discordant (50), the concen-
trations of the isoflavones present in the supplement tablets
used in the study were analytically evaluated. The values ob-
tained by HPLC analysis were in agreement to the declared
concentrations by the producer.
The menopause is an important moment for a woman, with a
number of subjects experiencing neurovegetatives symptoms,
like hot flushes, with an enormous impact on their quality of life
(51). Another unpleasant aspect of the menopausal transition
is the development of vaginal dryness, insomnia, irritation, anx-
iety and in the most serious cases, depression and memory
disturbances (52). The lack of the ovarian estrogen secretion
promotes also a number of disorders, such as cardiovascular
diseases, osteoporosis, metabolic diseases, genital prolapse
and, in some cases, dementia (53).
In order to prevent these diseases, the most valid and effica-
cious approach is represented by HRT (54). Nowadays, HRT
still represents the only recognised medical method approach
to counteract menopause-linked symptoms, even though sev-
eral women refuse this therapy because of growing concerns
of undesirable side effects (55). Alternative therapies, whose
the most popular are represented by phytoestrogens, require
more research, as criticisms are frequent and several answers
are still lacking. Results of clinical studies on the effects of soy
product or supplement based isoflavones on vasomotor symp-
toms are contradictory (56, 57) However recently, some pub-
lished studies showed the capability of isoflavones to reduce
neurovegetative symptoms, cardiovascular diseases and os-
teoporosis (11, 58, 59), then the use of isoflavones could be
considered for women with intense disorders. 
In this studied group, the results obtained are quite encourag-
ing for what concerns neurovegetative symptoms, such as in-
somnia, anxiety and mood disturbances. The most important
result is the reduction in number and intensity of hot flushes,
with a change of the Greene Climateric Scale value, from 3 to
1 or 0, without clinical modifications of the breast and uterine
tissues. Also the observations about bone metabolism are pos-
itive, in fact the BMD of the women was maintained stable,
even if a rapid worsening was expected after menopause. Our
clinical observations on neurovegetative symptoms are attribut-
able to isoflavones, the only active components of supplement
administered to the patients.
In conclusion, the expected results about circulating levels of
isoflavones metabolites, the dosage of the phytoestrogenic
supplements and the encouraging clinical results, together with
a high level of adherence to the phytoestrogenic administration
in the postmenopausal women, indicate this as an effective al-
ternative to HRT in the treatment of postmenopausal-related
symptoms. Future controlled clinical trials on these “alternative
remedies” would greatly contribute to confirm their long term
efficacy and safety.
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